Saratoga Research & Investment Management Has $75.84 Million Stake in Roche Holding AG (OTCMKTS:RHHBY)

Saratoga Research & Investment Management reduced its holdings in shares of Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,174,306 shares of the company's stock after selling 151,504 shares during the period. Roche accounts for about 3.8% of Saratoga Research & Investment Management's investment portfolio, making the stock its 10th largest holding. Saratoga Research & Investment Management's holdings in Roche were worth $75,840,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Bard Financial Services Inc. increased its stake in Roche by 156.8% in the 3rd quarter. Bard Financial Services Inc. now owns 80,500 shares of the company's stock worth $3,216,000 after buying an additional 49,150 shares in the last quarter. SVB Wealth LLC purchased a new stake in Roche during the 4th quarter valued at $555,000. IHT Wealth Management LLC purchased a new position in shares of Roche during the 3rd quarter worth about $236,000. Confluence Investment Management LLC raised its holdings in shares of Roche by 26.3% in the fourth quarter. Confluence Investment Management LLC now owns 13,981 shares of the company's stock worth $488,000 after buying an additional 2,910 shares during the period. Finally, Verity Asset Management Inc. lifted its position in shares of Roche by 26.8% during the fourth quarter. Verity Asset Management Inc. now owns 8,036 shares of the company's stock worth $280,000 after purchasing an additional 1,697 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. UBS Group upgraded Roche from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Sanford C. Bernstein upgraded shares of Roche to a "strong-buy" rating in a research report on Thursday, January 30th. Finally, Morgan Stanley started coverage on shares of Roche in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy".

Remove Ads

Roche Stock Performance

Shares of OTCMKTS RHHBY traded down $1.71 during midday trading on Thursday, hitting $39.37. The company had a trading volume of 2,987,788 shares, compared to its average volume of 3,225,474. Roche Holding AG has a twelve month low of $29.20 and a twelve month high of $44.31. The business has a 50-day simple moving average of $41.37 and a two-hundred day simple moving average of $38.73. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.